Search
BNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337ApprovedBNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19.
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalSipuleucel-T is a therapeutic cancer vaccine for prostate cancer. … It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data).
Metacycline
go.drugbank.com/drugs/DB00931ApprovedA broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseEchothiophate
go.drugbank.com/drugs/DB01057ApprovedInvestigationalA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Subasumstat
go.drugbank.com/drugs/DB16406InvestigationalSubasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced
Categories: Experimental Unapproved Treatments for COVID-19Testolactone
go.drugbank.com/drugs/DB00894ApprovedWithdrawnAn antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigational[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCarbimazole
go.drugbank.com/drugs/DB00389ApprovedAn imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.
Guaiacol
go.drugbank.com/drugs/DB11359ApprovedGuaiacol is an agent thought to have disinfectant properties and used as an expectorant. Guaiacol is a phenolic natural product first isolated from Guaiac resin and the oxidation of lignin.